Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PM54 |
| Synonyms | |
| Therapy Description |
PM54 is a lurbinectedin-derived transcriptional inhibitor which impairs mRNA synthesis, potentially resulting in enhanced antitumor immune response and inhibition of tumor growth (PMID: 39709435). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PM54 | PM-54|PM 54 | PM54 is a lurbinectedin-derived transcriptional inhibitor which impairs mRNA synthesis, potentially resulting in enhanced antitumor immune response and inhibition of tumor growth (PMID: 39709435). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |